Accuracy of the CUETO, EORTC 2016 and EAU 2021 scoring models and risk stratification tables to predict outcomes in high-grade non-muscle-invasive urothelial bladder cancer.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Krajewski Wojciech, Aumatell Júlia, Subiela José Daniel, Nowak Łukasz, Tukiendorf Andrzej, Moschini Marco, Basile Giuseppe, Poletajew Sławomir, Małkiewicz Bartosz, Del Giudice Francesco, Maggi Martina, Chung Benjamin I, Cimadamore Alessia, Galosi Andrea Benedetto, Fave Rocco Francesco Delle, D'Andrea David, Shariat Shahrokh F, Hornak Jakub, Babjuk Marko, Chorbińska Joanna, Teoh Jeremy Yuen-Chun, Muilwijk Tim, Joniau Steven, Tafuri Alessandro, Antonelli Alessandro, Panunzio Andrea, Alvarez-Maestro Mario, Simone Giuseppe, Mastroianni Riccardo, Łaszkiewicz Jan, Lonati Chiara, Zamboni Stefania, Simeone Claudio, Niedziela Łukasz, Candela Luigi, Macek Petr, Contieri Roberto, Hidalgo Beatriz Gutierrez, Rivas Juan Gomez, Sosnowski Roman, Mori Keiichiro, Mir Carmen, Soria Francesco, González-Padilla Daniel A, Faba Òscar Rodriguez, Palou Juan, Ploussard Guillaume, Rajwa Paweł, Hałoń Agnieszka, Laukhtina Ekaterina, Pradere Benjamin, Tully Karl, Burgos Francisco Javier, Cidre Miguel Ángel Jiménez, Szydełko Tomasz, European Association of Urology- Young Academic Urologists (EAU-YAU): Urothelial carcinoma working group
Аннотация
METHODS: The Kaplan-Meier estimates for recurrence-free survival and progression-free survival were performed, predictive abilities were assessed using the concordance index (C-index) and area under the curve (AUC).
RESULTS: A total of 1690 patients were included and the median follow-up was 51 months. For the overall cohort, the estimates recurrence-free survival and progression-free survival rates at 5-years were 57.1% and 82.3%, respectively. The CUETO scoring model had poor discrimination for disease recurrence (C-index/AUC for G2 and G3 grade tumors: 0.570/0.493 and 0.559/0.492) and both CUETO (C-index/AUC for G2 and G3 grade tumors: 0.634/0.521 and 0.622/0.525) EAU2021 (c-index/AUC: 0.644/0.522) had poor discrimination for disease progression.
CONCLUSION: Both the CUETO and EAU2021 scoring systems were able to successfully stratify risks in our population, but presented poor discriminative value in predicting clinical events. Due to the lack of data, model validation was not possible for EORTC2016. The CUETO and EAU2021 systems overestimated the risk, especially in highest-risk patients. The risk of progression according to EORTC2016 was slightly lower when compared with our population analysis.